Patents
Literature
26 results about "Docosapentaenoic acid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Docosapentaenoic acid (DPA) designates any straight chain 22:5 fatty acid, that is a straight chain open chain type of polyunsaturated fatty acid (PUFA) which contains 22 carbons and 5 double bonds. DPA is primarily used to designate two isomers, all-cis-4,7,10,13,16-docosapentaenoic acid (i.e. 4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid) and all-cis-7,10,13,16,19-docosapentaenoic acid (i.e. 7Z,10Z,13Z,16Z,19Z-docosapentaenoic acid). They are also commonly termed n-6 DPA and n-3 DPA, respectively; these designations describes the position of the double bond being 6 or 3 carbons closest to the (omega) carbon at the methyl end of the molecule and is based on the biologically important difference that n-6 and n-3 PUFA are separate PUFA classes, i.e. the omega-6 fatty acids and omega-3 fatty acids, respectively. Mammals, including humans, can not interconvert these two classes and therefore must obtain dietary essential PUFA fatty acids from both classes in order to maintain normal health (see essential fatty acids).
Application of docosapentaenoic acid in preparation of medicine for preventing and / or treating systemic lupus erythematosus
The invention discloses application of docosapentaenoic acid or medicinal salt thereof in preparation of a medicine for preventing and / or treating systemic lupus erythematosus. The invention aims to provide novel application of docosapentaenoic acid in treatment of systemic lupus erythematosus. In view of various immune abnormalities existing in the systemic lupus erythematosus morbidity process, the docosapentaenoic acid has potential application value in the field of systemic lupus erythematosus treatment due to the effects of regulating immune cell functions and improving immune microenvironment.
Owner:THE NAVAL MEDICAL UNIV OF PLA
Enzymes and methods for producing omega-3 fatty acids
The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desaturase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids. In particular, the present invention provides ω3 destaurases, Δ5 elongases and Δ6 desaturases with novel activities. Also provided are methods and DNA constructs for transiently and / or stably transforming cells, particularly plant cells, with multiple genes.
Owner:COMMONWEALTH SCI & IND RES ORG +1
Enzymes and methods for producing omega-3 fatty acids
The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desaturase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids. In particular, the present invention provides ω3 destaurases, Δ5 elongases and Δ6 desaturases with novel activities. Also provided are methods and DNA constructs for transiently and / or stably transforming cells, particularly plant cells, with multiple genes.
Owner:COMMONWEALTH SCI & IND RES ORG +1
Plasma metabolism marker combination for predicting human aging and application thereof
The invention discloses a biomarker composition for predicting the biological age or aging state of an individual, and the biomarker composition comprises tetracosyl saturated fatty acid / tetracosyl monounsaturated fatty acid phosphatidylcholine (PC 24: 0 / 14: 1), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine-cysteine tripeptide (Cys-Gly-Cys), cysteine-glycine- The invention relates to a pharmaceutical composition for the preparation of a pharmaceutical composition, which comprises the following components in parts by weight: 20: 0 / 22: 5, 20 / docosapentaenoic acid monohexosyl sphingosine amide (HexCer 20: 0 / 22: 5), trigonelline, lithocholic acid glycine (Lithocholic acid glycine), and octadecanoic saturated fatty acid / octadecanoic monounsaturated fatty acid phosphatidylcholine (PC 18: 0 / 18: 1). The biomarker can be used for accurately characterizing the aging state of an organism, and provides a strategy for early screening, intervention evaluation, accurate health management and the like of related diseases of the elderly.
Owner:UNIV OF SCI & TECH OF CHINA
Lipid comprising docosapentaenoic acid
ActiveJP2025063027ACosmetic preparationsOrganic chemistryStearidonic acidEPA - Eicosapentaenoic acid
To provide extracted plant lipid or microbial lipid comprising docosapentaenoic acid (DPA), and processes for producing the extracted lipid.SOLUTION: Provided is extracted plant lipid or microbial lipid, comprising fatty acids in an esterified form, the fatty acids comprising oleic acid, palmitic acid, ω6 fatty acids which comprise linoleic acid (LA), ω3 fatty acids which comprise α-linolenic acid (ALA) and docosapentaenoic acid (DPA), and optionally one or more of stearidonic acid (SDA), eicosapentaenoic acid (EPA), and eicosatetraenoic acid (ETA), wherein the level of DPA in the total fatty acid content of the extracted lipid is between 7% and 35%.SELECTED DRAWING: None
Owner:COMMONWEALTH SCI & IND RES ORG +2
Omega-3 compositions and methods relating thereto
ActiveUS12491174B2Organic active ingredientsEmulsion deliveryDHA - Docosahexaenoic acidAqueous solubility
The present invention provides for a water-soluble composition comprising at least one source of Omega-3 comprising at least one Omega-3 fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and alpha-linolenic acid (ALA), and micelle-promoting agents comprising one or more of carrier oils, solvents, emulsiiiers and antioxidants, in order to promote an increase in biovailability of the Omega-3 Source of at least two times.
Owner:PHARMAKO BIOTECH PTY LTD
Specific metabolism marker combination for identifying drying mode of high-calcium vegetable ox ear powder and application of specific metabolism marker combination
The invention belongs to the technical field of food processing and quality safety control, and particularly relates to a specific metabolic marker combination for identifying a drying mode of high-calcium vegetable ox ear powder and application of the specific metabolic marker combination. The metabolic marker composition is prepared from 12 kinds of metabolites, namely, larch sibirica flavone, 9-Methyl-arylchromenone, larch resinol, docosapentaenoic acid, gibberellin A7, methyl-arylpyranone, docosapentaenoyl glycerophosphorylcholine, Cratoxyborenone E, heptanol, prenylflavonoids, pteridin-6-carboxylic acid and Garcimangosone B. The invention further discloses a preparation method of the metabolic marker composition. The metabolic marker combination provided by the invention can be used for carrying out production process traceability and authenticity identification on the high-calcium vegetable ox ear powder, and can be used as a basis for evaluating a product drying process quality standard and monitoring the consistency of a drying process.
Owner:江西省 中国科学院庐山植物园
Cyclodextrin complexes of specialized proresolving mediators
PendingUS20260151505A1Organic active ingredientsPharmaceutical non-active ingredientsCyclodextrinDouble bond
The present invention provides complexes of a specialized pro-resolving mediator (SPM), or a salt, ester, or amide thereof, and a cyclodextrin (CD), wherein the SPM is a hydroxylated, polyunsaturated fatty acid derived from arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, or docosapentaenoic acid, 20 or 22 carbon atoms in length, with 4, 5 or 6 conjugated double bonds arranged in diene, triene, or tetraene systems or combinations thereof, and related compositions and methods.
Owner:THETIS PHARMACEUTICALS LLC
Application of rhizoma smilacis glabrae in preparation of medicine for treating intestinal flora and / or metabolic disorder caused by hyperuricemia
The invention provides application of rhizoma smilacis glabrae in preparation of a medicine for treating intestinal flora and / or metabolic disorder caused by hyperuricemia. The application is realized by regulating and controlling the expression level of SUA-associated metabolic markers in serum. The SUA-associated metabolic markers comprise: metabolites positively associated with SUA, wherein the metabolites comprise chenodeoxycholic acid, nutritional cholic acid, 7alpha-hydroxy-3-oxo-4-cholesteric acid and ceramyl ethanolamide; eight metabolites which are in negative correlation with SUA comprise polyterpene alcohol group-beta-D-glucosyl phosphate, docosapentaenoic acid, 5, 8, 11-eicosatrienoic acid, adrenoic acid, diacylglycerol DG (16: 0 / 22: 5), phosphatidylcholine PC (14: 0 / 18: 1), phosphatidylcholine PC (18: 0 / 22: 6) and retinyl ester.
Owner:SHANGHAI JIAOTONG UNIV
Cyclodextrin complexes for specifying
PendingCN119136842AOrganic active ingredientsPharmaceutical non-active ingredientsCyclodextrinDouble bond
The present invention provides complexes of a specialized proregression mediator (SPM), or a salt, ester or amide thereof, with cyclodextrin (CD) wherein the SPM is a hydroxylated polyunsaturated fatty acid derived from arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid or docosapentaenoic acid, having a length of 20 or 22 carbon atoms, having a length of 20 or 22 carbon atoms, having a length of 20 or 22 carbon atoms, having a length of 20 or 22 carbon atoms, and having a length of 20 or 22 carbon atoms; 4, 5 or 6 conjugated double bonds are disposed in a diene, triene or tetraene system or a combination thereof; and related compositions and methods.
Owner:THETIS PHARMACEUTICALS LLC
Anti-inflammatory composition and use
PCT designated stage expiredWO2025153832A1Organic active ingredientsNervous disorderDocosatrienoic AcidStearic acid
8Z, 11Z, 14Z, 17Z-eicosatetraenoic acid (ETA) and / or 10Z, 13Z, 16Z-docosa-10,l 3, 16-trienoic acid (DTA) have been shown to have anti-neuroinflammatory properties and suitable for use in the treatment of neurodegenerative disease, such as Alzheimer's disease. The anti-neuroinflammatory effect of using ETA and / or DTA can be surprisingly, and optionally synergistically increased by using ETA and / or DTA in combination with eicosapentaenoic acid (EPA),docosahexaenoic acid (DHA), stearidonic acid (6, 9, 12, 15 -octadecatrienioc acid) (SDA), gamma linolenic acid (6, 9, 12-octadecatrienioc acid) (GLA), dihomo γ linolenic acid (8, 11, 14-eicosatraenoic acid) (DGLA), and / or 7, 10, 13, 16, 19-docosapentaenoic acid (DPA), preferably docosahexaenoic acid (DHA).
Owner:NORTHWOOD CONSULTANTS LTD
HA / CS / dECM-AD hydrogel medicine and application thereof in treatment of osteoarthritis
The invention belongs to the technical field of biological medicine, and particularly relates to a HA / CS / dECM-AD hydrogel medicine and application thereof in treatment of osteoarthritis, the hydrogel medicine is composed of a three-dimensional network composed of hyaluronic acid (HA), chitosan (CS) and a decellularized extracellular matrix (dECM), and two active ingredients of atorvastatin (Ato) and docosapentaenoic acid (DPA) are loaded in the three-dimensional network. The hydrogel has the following characteristics: a dual slow-release mechanism is adopted, Ato is quickly released within 2 hours, and DPA is accumulatively released by 70-90% within 7 days through PDA nanoparticles; according to biological activity induction, the dECM derived from hiPSCs retains cartilage specific components such as type II collagen (COL2) and aggregation protein glycan (ACAN), and cartilage cell proliferation is promoted; and the retention time in the articular cavity exceeds 6 weeks. Animal experiments show that the hydrogel can remarkably repair cartilage defects, inhibit M1 type macrophage infiltration and reduce expression of proinflammatory factors such as IL-1beta and TNF-alpha.
Owner:THE AFFILIATED HOSPITAL OF QINGDAO UNIV
Lipid comprising docosapentaenoic acid
The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.
Owner:NUSEED NUTRITIONAL AUSTRALIA PTY LTD +2
Method for supporting memory function and / or cognitive function
The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and / or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and / or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and / or therapeutically supporting memory and / or cognitive function in a human subject in need thereof.
Owner:NV NUTRICIA
Serological biomarkers for diagnosing chronic obstructive pulmonary disease
PendingCN121027355AComponent separationAnalysis using nuclear magnetic resonanceDiseaseArachidic acid
The invention relates to the technical field of biomedicine, in particular to a serological biomarker for diagnosing chronic obstructive pulmonary disease. The marker is selected from the group consisting of myristic acid, oleic acid, stearic acid, eicosapentaenoic acid, arachidic acid, docosahexaenoic acid, docosapentaenoic acid, docosatetraenoic acid, nervonic acid, wood tar acid, arginine and glutamine. The combined marker has relatively high sensitivity and specificity, can provide reliable diagnosis information in an early stage or an atypical stage of symptoms, and overcomes the limitations of dependence on lung function detection, insufficient sensitivity, complex operation and the like of the existing diagnosis means; therefore, a convenient and accurate detection tool capable of being popularized is provided for early screening, risk prediction and clinical diagnosis of the chronic obstructive pulmonary disease.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL
Brassica Plants Producing Elevated Levels of Polyunsaturated Fatty Acids
PendingUS20260174024A1Plant peptidesVector-based foreign material introductionBrassica creticaGenetics
Provided herein are Brassica plants that produce one or more of omega-3 docosapentaenoic acid (DHA), docosapentaenoic acid (DPA), and eicosapentaenoic acid (EPA), and methods of making such plants.
Owner:BASF PLANT SCI GMBH
Adipose tissue lipid metabolite for evaluating fat health state and detection kit and application of adipose tissue lipid metabolite
PendingCN119643884AEvaluation is direct and fastAccurate individual pathological status dataOrganic active ingredientsMetabolism disorderDiseaseMetabolite
The invention relates to adipose tissue lipid metabolites for evaluating the health state of fat and a detection kit and application of the adipose tissue lipid metabolites. Specifically, the lipid metabolites arachidonic acid and docosapentaenoic acid can be used as markers for evaluating the health state of adipose tissue metabolism; the arachidonic acid can be used for improving obesity metabolic disorder; according to the kit, fat tissue lipid metabolites are rapidly detected, so that the fat tissue is directly and rapidly evaluated; according to the detection kit, the technical requirements on operators are reduced, the operation steps are simplified, and the detection kit can be applied on a large scale, so that early detection and prevention and treatment of obesity-related diseases are improved.
Owner:SHANGHAI TENTH PEOPLES HOSPITAL
COMPOSITIONS HAVING HIGH LEVELS OF DPA (n-3) AND METHODS FOR PRODUCING
Disclosed herein are compositions produced from microorganisms that are capable of producing high levels of docosapentaenoic acid (DPA(n-3)), and methods for producing the compositions. The invention is further directed to microbial strains and derivatives therefrom, biomasses, and microbial oils.
Owner:DSM IP ASSETS BV
Lipid comprising docosapentaenoic
The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.
Owner:GRAINS RES & DEV CORP +2
Capillary shape improver
To provide a food composition and a pharmaceutical composition suitable for use as a capillary shape improver that can effectively improve a capillary shape even when consumed at low dosages, while ensuring safety and stable supply.SOLUTION: The present invention provides a capillary shape improver for oral administration that comprises any one of microalgae containing n-6 docosapentaenoic acid (n-6DPA), a fatty acid composition containing n-6DPA, and n-6DPA.SELECTED DRAWING: None
Owner:SOPROS INC
Plant lipids containing eicosapentaenoic acid, extracted
The present invention relates to an extracted plant lipid containing docosahexaenoic acid, and a method for producing the extracted plant lipid.
Owner:COMMONWEALTH SCI & IND RES ORG +2
Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids
The present invention relates to lipid comprising docosapentaenoic acid and / or docosahexaenoic acid wherein the docosapentaenoic acid and / or docosahexaenoic acid may be preferentially esterified at the sn-2 position of triacylglycerol, and processes for producing and using the lipid.
Owner:GRAINS RES & DEV CORP +1
Lipid comprising docosapentaenoic
The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.
Owner:COMMONWEALTH SCI & IND RES ORG +2
Lipid comprising docosapentaenoic acid
The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.
Owner:COMMONWEALTH SCI & IND RES ORG +2
Oral hair growth promoter
To provide a food composition, a feed composition, and a pharmaceutical composition which exhibit a hair growth effect even with a small amount of intake and serve as a hair growth promoter with safety and supply stability.SOLUTION: A hair growth promoter according to the present invention comprises one selected from a microalga containing n-6DPA (n-6 docosapentaenoic acid), a fatty acid composition containing n-6DPA, and n-6DPA, and is intended for oral ingestion.SELECTED DRAWING: None
Owner:SOPROS INC
CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORS
The present invention provides complexes of specific pro-degradation mediators (SPMs), or salts, esters, or amides thereof, and cyclodextrin (CD), where the SPMs are hydroxylated polyunsaturated fatty acids derived from arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, or docosapentaenoic acid, 20 or 22 carbon atoms in length and with 4, 5, or 6 conjugated double bonds arranged in a diene, triene, or tetraene system, or combinations thereof; and related compositions and methods.
Owner:THETIS PHARMACEUTICALS LLC